Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
Büchner T, Hiddemann W, Wörmann B, Löffler H, Ludwig WD, Schoch C, Haferlach T, Maschmeyer G, Staib P, Aul C, Heyll GA, Grüneisen A, Rasche H, Eimermacher JH, Balleisen L, Pielken HJ, Reis HE, Griesinger F, Reichle A, Sauerland MC, Heinecke A; German AMLCG. Büchner T, et al. Among authors: reichle a. Int J Hematol. 2000 Oct;72(3):285-9. Int J Hematol. 2000. PMID: 11185983
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Hiddemann W, Aul HC, Maschmeyer G, Urbanitz D, Lathan B, Reichle A, Köppler H, Donhuijsen-Ant R, Ludwig WD, Grüneisen T, et al. Hiddemann W, et al. Among authors: reichle a. Haematol Blood Transfus. 1990;33:604-10. doi: 10.1007/978-3-642-74643-7_110. Haematol Blood Transfus. 1990. PMID: 2182450 Clinical Trial. No abstract available.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: reichle a. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
Treatment of older patients with AML.
Büchner T, Berdel WE, Wörmann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Grüneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J, Hiddemann W. Büchner T, et al. Among authors: reichle a. Crit Rev Oncol Hematol. 2005 Nov;56(2):247-59. doi: 10.1016/j.critrevonc.2004.09.010. Epub 2005 Oct 21. Crit Rev Oncol Hematol. 2005. PMID: 16246568 Review.
Treatment of AML in biological subgroups.
Buechner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Schnittger S, Kern W, Tchinda J, Reichle A, Staib P, Ludwig WD, Aul C, Sauerland MC, Heinecke A, Woermann B, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Buechner T, et al. Among authors: reichle a. Hematology. 2005;10 Suppl 1:281-85. doi: 10.1080/10245330512331390212. Hematology. 2005. PMID: 16276628 Free article. Review. No abstract available.
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: reichle a. Blood. 2006 Sep 1;108(5):1469-77. doi: 10.1182/blood-2005-11-4386. Epub 2006 Apr 25. Blood. 2006. PMID: 16638934 Free article. Clinical Trial.
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: reichle a. J Clin Oncol. 2006 Jun 1;24(16):2480-9. doi: 10.1200/JCO.2005.04.5013. J Clin Oncol. 2006. PMID: 16735702 Clinical Trial.
132 results